Related Experiment Videos
Resistance to protease inhibitors.
1Partners AIDS Research Center, Cambridge, MA 02139, USA. dkuritzkes@partners.org
Journal of HIV Therapy
|May 8, 2003
Summary
HIV-1 protease inhibitor resistance complicates treatment, with initial resistance patterns varying by drug and viral subtype. New drugs are needed to overcome resistance and improve patient outcomes in highly active antiretroviral therapy.
Area of Science:
- Virology
- Immunology
- Pharmacology
Background:
- Highly active antiretroviral therapy (HAART) effectiveness is limited by resistance to HIV-1 protease inhibitors (PIs).
- Selection of salvage therapy is complicated by the growing number of patients with PI resistance.
- Initial resistance patterns are influenced by the specific PI, viral subtype, and drug exposure levels.
Purpose of the Study:
- To review the factors influencing the development of HIV-1 protease inhibitor resistance.
- To discuss the impact of PI resistance on viral replication capacity and immunological status.
- To highlight the need for novel therapeutic strategies against PI-resistant HIV-1.
Main Methods:
- Literature review of studies on HIV-1 protease inhibitor resistance.
- Analysis of factors affecting resistance development and viral evolution.
- Evaluation of current and potential therapeutic interventions.
Main Results:
- Impaired replication capacity of early PI-resistant viruses can maintain immunological stability.
- Accumulation of further mutations leads to increased drug resistance and immunological decline.
- Pharmacological enhancement of plasma PI levels can partially overcome resistance.
Conclusions:
- HIV-1 protease inhibitor resistance is a significant clinical challenge.
- Understanding resistance mechanisms is crucial for effective treatment selection.
- Development of new drugs active against PI-resistant HIV-1 is essential.